1. Home
  2. BCX vs PHAT Comparison

BCX vs PHAT Comparison

Compare BCX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Resources of Beneficial Interest

BCX

BlackRock Resources of Beneficial Interest

HOLD

Current Price

$12.88

Market Cap

898.8M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$8.39

Market Cap

759.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCX
PHAT
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.8M
759.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BCX
PHAT
Price
$12.88
$8.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$19.83
AVG Volume (30 Days)
146.2K
1.0M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
6.99%
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
N/A
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$9.68
$8.21
52 Week High
$13.86
$18.31

Technical Indicators

Market Signals
Indicator
BCX
PHAT
Relative Strength Index (RSI) 55.39 38.84
Support Level $11.90 N/A
Resistance Level $13.05 $9.74
Average True Range (ATR) 0.21 0.46
MACD -0.05 0.02
Stochastic Oscillator 15.81 9.03

Price Performance

Historical Comparison
BCX
PHAT

About BCX BlackRock Resources of Beneficial Interest

BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies, or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: